


A Patient's Journey: An Example of Accessing New Alzheimer's Treatments Through Medicare Part B

Last year, for the first time, research led to an entirely new class of therapies directed at the underlying cause of Alzheimer's disease, with one such therapy already FDA-approved. Unfortunately, the Centers for Medicare & Medicaid Services (CMS) has finalized a coverage determination that severely restricts patient access to these medicines even if the patient matches the criteria for the intended patient population. Let's take a closer look at some of the barriers seniors with Alzheimer's could face in attempting to access this class of treatments.



While biopharmaceutical companies have made tremendous progress in scientific and medical innovations for neurodegenerative diseases like Alzheimer's over the past decade, efforts are in vain if patients are prevented from accessing these life-altering treatments.